“I can confirm that we have received another report of a suspected death linked to vaccination last week,” writes Veronica Arthurson, unit manager at the Medical Products Agency in a text message to SVT. The woman in her 70s was completely healthy when she was vaccinated with Astra Zeneca’s vaccine, according to relatives. A few days later, she got the unusual side effects – blood clots and low levels of platelets – which have been the focus of the EU Medicines Agency’s review of the vaccine, according to SVT.
Seven people suffered from partial paralysis after receiving the Sinovac vaccine, a doctor from Chulalongkorn University said. Six of them were in Rayong and one at the Queen Savang Vadhana Memorial Hospital in Chon Buri’s Sri Racha district. Their conditions improved after doctors administered medication to dissolve blood clots.
The TGA’s Vaccine Safety Investigation Group (VSIG) met late today and concluded that a recently reported case of thrombosis (blood clots in the arteries and veins) with thrombocytopenia (low platelet count) is likely to be linked to vaccination. VSIG reviewed a report about a 48-year-old woman who was vaccinated in New South Wales and admitted to hospital with an extensive thromboembolic event and thrombocytopenia (TTS) four days after receiving the AstraZeneca COVID-19 Vaccine. Sadly,
this person Genene Norris died in hospital and we extend our sincerest condolences to her family.
RIP Genene Norris
“Up to 5 April 2021, the MHRA had received Yellow Card reports of 100 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following vaccination with COVID-19 Vaccine AstraZeneca. These events occurred in 61 women and 39 men aged from 18 to 85 years and the overall case fatality rate was 22% with 22 deaths.
Of these, 99 reports were associated with the first dose of the vaccine and a single report followed a second dose, although this individual had medical conditions that could have caused the events. Fifty individuals had cerebral venous sinus thrombosis (average age 46 years) and 50 had other major thromboembolic events (average age 52 years) with concurrent thrombocytopenia.”
Denmark has received the first claim for compensation for a death caused by a special type of blood clot, which the authorities link with the Astrazeneca vaccine. The patient compensation scheme has received a total of 29 compensation applications from citizens who have received the Astrazeneca vaccine. A further eight cases concern the Pfizer vaccine. There are no claims for Moderna.
This is stated by Patienterstatningen, which handles cases of compensation for citizens who are affected by serious side effects from e.g. medicines.
After her first vaccination with Astrazeneca, the 43-year-old nurse Tina Sylvester Rohrmann from Nyborg was hit by blood clots in her lungs. She is sure that there is a connection with the vaccine. The doctors at OUH in Svendborg think the same, she says. The Funen nurse fully supports vaccines. Just not the one from Astrazeneca.
Avisendanmark report (paywall)
The [South Korean] government is temporarily suspending AstraZeneca vaccines for people under 60 after a third blood clot developed in a patient after an AstraZeneca shot. Korea’s Covid-19 vaccination Task Force team said Wednesday that a medical worker in her 20s was diagnosed with blood clots in her legs and lungs twelve days after she got her first AstraZeneca jab on March 17. She developed shortness of breath on March 29. This was the third case of blood clot problems following AstraZeneca inoculations.
Previously, a blood clot was found during an autopsy of a patient in her 60s who died after inoculation. In the second case, a paramedic in his 20s was diagnosed with cerebral venous sinus thrombosis (CVST), or a brain blood clot, but he received treatment and recovered.
In Annecy, the family of a 63-year-old man who died on March 18, eleven days after being vaccinated against Covid-19 with a dose of AstraZeneca vaccine, confirmed they have filed a complaint against [persons unknown] for involuntary homicide.
On March 7, 63-year-old Joël Crochet received a first dose of AstraZeneca vaccine during the mass vaccination operation organized on the Pâquier in Annecy.
“Thirty minutes after the injection, he felt quite severe joint pain and then respiratory problems”, explains his brother. The next day, the sixty-year-old went to his doctor who prescribed treatment. But a week later, this man’s health suddenly worsened. “On Wednesday, March 17, he was hospitalized, continues Jean-Luc Crochet. “…Doctors have detected several thromboses in the liver, kidneys and brain…” He died on Thursday March 18.
A vaccine trial into the safety and efficacy of the Oxford/AstraZeneca vaccine in children has been paused while the UK medicines regulator investigates a possible link to rare blood clots in adults who had the jab.
A spokesperson from Oxford university said in a statement: “Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA on its review of rare cases of thrombosis/thrombocytopaenia that have been reported in adults, before giving any further vaccinations in the trial. Parents and children should continue to attend all scheduled visits and can contact the trial sites if they have any questions.”
Marco Cavaleri is responsible for the vaccine strategy of EMA, the European drug agency. “Cases are extremely rare and the risk-benefit balance is always in favour of vaccines. But now it is increasingly difficult to say that there is no cause and effect relationship between vaccination with AstraZeneca and very rare cases of unusual blood clots associated with low platelet counts.”
Il Messaggero report (in Italian)
Ireland’s Health Products Regulatory Authority (HPRA) has said it has received 16 reports of blood clots occurring following vaccination with the AstraZeneca Covid-19 vaccine. It said that none describe a rare blood clot. The figures are up to the end of March.
The HPRA said that none of the reports describe cerebral venous sinus thrombosis, which is a rare type of blood clot in the brain, nor the occurrence of a blood clot associated with low platelets.
Britain has identified 30 cases of rare blood clot events following the use of the AstraZeneca vaccine — 25 more than initially reported.
The Medicines and Healthcare products Regulatory Agency (MHRA) maintained that the benefits of the vaccine in the prevention of Covid-19 far outweighed any potential risk of blood clots.
Yesterday it put the total count of reported cases of the extremely rare brain clotting ailment, cerebral venous sinus thrombosis, at 22 and the number of reports of other clotting events associated with low blood platelets at eight.
By March 29, 2021, 31 cases of sinus vein thrombosis after vaccination with the COVID-19 vaccine from AstraZeneca (Vaxzevria) were reported to the Paul Ehrlich Institute as part of the spontaneous recording. Thrombocytopenia was also reported in 19 cases. The outcome was fatal in nine cases.
With the exception of two cases, all reports concerned women aged 20 to 63 years. The two men were 36 and 57 years old. The very rare cases of cerebral vein thrombosis were only reported to the Paul Ehrlich Institute after the first vaccination.
Canada’s National Advisory Committee on Immunization is recommending a pause on AstraZeneca COVID-19 vaccinations for people under 55 for safety reasons, a person familiar with the matter told The Associated Press on Monday.